Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29323
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorIVANOVIC, Renato F.-
dc.contributor.authorVIANA, Nayara I.-
dc.contributor.authorMORAIS, Denis R.-
dc.contributor.authorMOURA, Caio-
dc.contributor.authorSILVA, Iran A.-
dc.contributor.authorLEITE, Katia R.-
dc.contributor.authorPONTES-JUNIOR, Jose-
dc.contributor.authorNAHAS, William C.-
dc.contributor.authorSROUGI, Miguel-
dc.contributor.authorREIS, Sabrina T.-
dc.date.accessioned2018-11-21T16:59:15Z-
dc.date.available2018-11-21T16:59:15Z-
dc.date.issued2018-
dc.identifier.citationBMC CANCER, v.18, article ID 992, 6p, 2018-
dc.identifier.issn1471-2407-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29323-
dc.description.abstractBackgroundThe imbalance between the action of the tissue inhibitors of matrix metalloproteinases (TIMPs) and the matrix metalloproteinases (MMPs) is one component of metastasis physiology. TIMP-1 overrides MMP-9 activity in cancer and might be regulated by miR-618. The aims of this study were to clarify whether TIMP-1 expression is modified by miR-618 and to clarify the effect of miR-618 expression on the invasion of prostate cancer cells. We also studied miR-618 expression in surgical specimens of patients with localized prostate cancer submitted to open radical prostatectomy.MethodsAfter transfection of miR-618 or its antagonist in DU145 cells, qRT-PCR for TIMP-1/MMP-9 and both ELISA and zymography for MMP-9 were performed. Total miRNA was extracted from surgical specimens of PCa, and miR-618 expression was examined for correlations with Gleason score, pathological status and biochemical recurrence.ResultsDU145 cells transfected with miR-618 had a 76% reduction in TIMP-1 expression relative to control cells (p=0.003). miR-618 inhibition reduced MMP-9 expression by 31% (p=0.032) and MMP-9 absorbance evaluated with ELISA assay (p=0.06).Zymography suggested higher MMP-9 activity in DU145 cells transfected with miR-618 than those transfected with miR-618 inhibitor, but the difference was not significant (p=0.55). However, miR-618 expression was lower in surgical specimens of patients with Gleason score>7 (p=0.08) and more advanced disease (p=0.07).ConclusionsIn vitro, miR-618 overexpression decreases TIMP-1 and miR-618 inhibition decreases MMP-9, suggesting that miR-618 might be an oncomiR. However, the analysis of clinical samples of localized prostate cancer revealed an inconsistent pattern, as increased miR-618 expression was associated with lower Gleason score and pathological status. Further studies are needed to address whether miR-618 is a context-dependent miRNA.-
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo [2015/00845-6, 2012/21833-8]-
dc.language.isoeng-
dc.publisherBMC-
dc.relation.ispartofBMC Cancer-
dc.rightsopenAccess-
dc.subjectProstate cancer-
dc.subjectMMP-9-
dc.subjectTIMP-1-
dc.subjectmicroRNA-
dc.subjectInvasion-
dc.subject.othermatrix metalloproteinases-
dc.subject.othermessenger-rna-
dc.subject.otherbiomarkers-
dc.subject.otherinhibitors-
dc.subject.othertissue-
dc.subject.otherprognosis-
dc.titlemiR-618: possible control over TIMP-1 and its expression in localized prostate cancer-
dc.typearticle-
dc.rights.holderCopyright BMC-
dc.identifier.doi10.1186/s12885-018-4930-4-
dc.identifier.pmid30340564
dc.subject.wosOncology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.articlenumber992-
hcfmusp.description.volume18-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000447737100007-
hcfmusp.origem.id2-s2.0-85055077806-
hcfmusp.publisher.cityLONDON-
hcfmusp.publisher.countryENGLAND-
hcfmusp.relation.referenceAbdalla MAK, 2012, J CANCER, V3, P19, DOI 10.7150/jca.3.19-
hcfmusp.relation.referenceBAKER T, 1994, BRIT J CANCER, V70, P506, DOI 10.1038/bjc.1994.336-
hcfmusp.relation.referenceBhavsar T, 2013, SEMIN ONCOL, V40, P259, DOI 10.1053/j.seminoncol.2013.04.002-
hcfmusp.relation.referenceBickers B, 2009, ANTICANCER RES, V29, P3289-
hcfmusp.relation.referenceHa M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838-
hcfmusp.relation.referenceLeite KRM, 2013, CLINICS, V68, P797, DOI 10.6061/clinics/2013(06)12-
hcfmusp.relation.referenceLi P, 2013, MOL CELL BIOCHEM, V384, P1, DOI 10.1007/s11010-013-1775-7-
hcfmusp.relation.referenceLichtinghagen R, 2003, ANTICANCER RES, V23, P2617-
hcfmusp.relation.referenceLivak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262-
hcfmusp.relation.referenceLOKESHWAR BL, 1993, CANCER RES, V53, P4493-
hcfmusp.relation.referenceLu YC, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-218-
hcfmusp.relation.referencePloussard G, 2010, NAT REV UROL, V7, P101, DOI 10.1038/nrurol.2009.261-
hcfmusp.relation.referenceReis ST, 2011, INT J BIOL MARKER, V26, P255, DOI 10.5301/JBM.2011.8831-
hcfmusp.relation.referenceSong XL, 2017, J CANCER, V8, P2501, DOI 10.7150/jca.17407-
hcfmusp.relation.referenceStill K, 2000, PROSTATE, V42, P18-
hcfmusp.relation.referenceWood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388-
hcfmusp.relation.referenceWu XF, 2013, CANCER PREV RES, V6, P196, DOI 10.1158/1940-6207.CAPR-12-0276-
dc.description.indexMEDLINE-
hcfmusp.citation.scopus6-
hcfmusp.scopus.lastupdate2022-06-17-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCG
Departamento de Cirurgia - FM/MCG

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/55
LIM/55 - Laboratório de Urologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_IVANOVIC_miR618_possible_control_over_TIMP1_and_its_expression_2018.PDFpublishedVersion (English)758.12 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.